Highlights Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Delayed OTC Markets Other stock markets 07:31:58 01/04/2024 pm IST			5-day change	1st Jan Change
19.48 ^USD	+4.39%		-.--%	-6.75%

21/05	Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug	MT
07/05	Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	07/05	CI
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04	MT
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04	CI
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	02/04	CI
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	21/03	MT
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	07/03	CI
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	05/03	MT
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	05/03	CI
Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease	20/02	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02	RE
Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China	07/02	CI
Innovent Biologics Posts 65% Revenue Growth in Q4 of 2023	06/02	MT
Innovent Bio's Weight Management Drug Trial Meets Primary and Secondary Endpoints	09/01	MT
Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints	09/01	CI
Innovent Biologics, Inc. and Sanegene Bio USA Inc. Enter Strategic Collaboration to Develop Sirna Drug for the Treatment of Hypertension	27/12	CI
China?S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application of Taletrectinib	18/12	CI
Innovent Biologics, Inc. Announces Publication of Mazdutide Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications	18/12	CI
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study	07/12	CI
Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma	06/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Highlights

Filters